Purpose Limited data are available on cabazitaxel pharmacokinetics in patients with renal
impairment. This open-label, multicenter study assessed cabazitaxel in patients with …

e566 Background: Cabazitaxel is an approved second-line treatment in metastatic castration-
resistant prostate cancer therapy with a significant survival benefit compared to …

Purpose Cabazitaxel is primarily metabolized by CYP3A. This study evaluated the impact of
moderate/strong CYP3A inhibitors [aprepitant (Study Part 2); ketoconazole (Study Part 3)] or …

Purpose To develop a population pharmacokinetic (PK) model for cabazitaxel in patients
with advanced solid tumors and examine the influence of demographic and baseline …

Purpose Cabazitaxel has not been studied in patients with hepatic impairment (HI). This
phase I study assessed cabazitaxel safety and pharmacokinetics in patients with HI …

BACKGROUND: Although the taxanes paclitaxel and docetaxel are among the most active
agents for the treatment of a wide range of cancers, tumours often develop resistance to …

Taxane–gemcitabine combinations have demonstrated antitumor activity. This phase I study
(NCT01001221) aimed to determine the maximum tolerated dose (MTD) and dose-limiting …

Introduction Cabazitaxel is a second-generation taxane with in vivo activity against taxane-
sensitive and-resistant tumor cell lines and tumor xenografts. Cabazitaxel/cisplatin have …

Purpose The purpose of the study is to analyze the pharmacokinetic (PK) profile of
cabazitaxel and evaluate its safety and tolerability as a 1-h IV infusion every 3 weeks in …

Abstract Background This phase 1/2 study (NCT01751308) evaluated cabazitaxel in
pediatric patients. Phase 1 determined the maximum tolerated dose (MTD) in patients with …